title: Epirubicin in combination chemotherapy in the treatment of advanced stage non-Hodgkin's lymphomas.
abstract: From April 1981 to May 1984, 23 patients with advanced non-Hodgkin's lymphomas were treated with CEOP (cyclophosphamide, epirubicin, vincristine, and prednisone) or OEPP (vincristine, epirubicin, procarbazine, and prednisone) combination chemotherapy. CR was achieved in 58% and PR in 31% of the patients, giving an overall response rate of 89%. Nine of 15 (60%) previously untreated patients with unfavorable histology obtained a CR and 5 a PR. Median relapse-free survival was 33 months; median overall survival has not yet been reached, and the probability of survival for CRs was 91% after 54 months of follow-up. Acute toxicity was quite acceptable, and chronic cardiac toxicity was detected in 6 patients only. In conclusion, epirubicin used in combination chemotherapies induced durable remissions and prolonged survivals in advanced non-Hodgkin's lymphomas.
authors.forename: G
authors.initials: G
authors.lastname: Abate
authors.forename: P
authors.initials: P
authors.lastname: Comella
authors.forename: N
authors.initials: N
authors.lastname: Di Pietro
authors.forename: F
authors.initials: F
authors.lastname: Ganzina
authors.forename: M
authors.initials: M
authors.lastname: Pergola
authors.forename: P
authors.initials: P
authors.lastname: Silvestro
authors.forename: A
authors.initials: A
authors.lastname: Basso
authors.forename: M
authors.initials: M
authors.lastname: Salvatore
authors.forename: D
authors.initials: D
authors.lastname: Zarrilli
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000139:chemically induced; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D015251:Epirubicin; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D011344:Procarbazine; D015251:Epirubicin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone